CORTCorcept Therapeutics Inc. — stock analysis & sentiment

Corcept closes at $110.77, near the upper end of a 52-week band that runs from $28.66 to $122.21. That range is unusually wide — the low sits roughly a quarter of the high — so the last year has involved a large repricing rather than steady drift, and the current level sits closer to where the stock has recently traded at its strongest than to where it began the span.

The market is valuing the business at about $12.0 billion, or roughly 236 times trailing earnings and 16.9 times book value. That trailing multiple sits far above the forward multiple of about 24.5, a gap that reflects expected earnings well above what the last twelve months produced. The underlying profitability is thinner than the multiple alone would imply: net margin is about 6.6%, with revenue growing roughly 31.7% year over year. Beta of 0.455 means the shares have historically moved less than half as much as the broad market, so the price swings here have come more from company-specific developments than from market direction.

The news flow is heavily company-specific and split between two distinct threads. April 2026 brought a dense cluster of law-firm notices tied to a securities class action, with several referencing an April 21 lead plaintiff deadline and one connecting the case to a relacorilant setback. A July 2026 item covers insider share sales following an FDA approval and a $1.05 billion outlook. Only one recent headline is sector-level rather than company-level: a June 2026 comparison of pharmaceutical and biotech ETFs.